Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease

Parkinson’s Disease

Developing and validating Parkinson's disease subtypes and their motor and cognitive progression

J Neurol Neurosurg Psychiatry.

Lawton M, Ben-Shlomo Y, May MT, Baig F, Barber TR, Klein JC, Swallow DMA, Malek N, Grosset KA, Bajaj N, Barker RA, Williams N, Burn DJ, Foltynie T, Morris HR, Wood NW, Grosset DG, Hu MTM

doi: 10.1136/jnnp-2018-318337.

Aging and Cognitive FunctionsAnxiety and Depression

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts

Lancet Neurol.

Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR

doi: 10.1016/

RECOMMENDED

Parkinson’s Disease

Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease

Parkinsonism Relat Disord.

Contin M, Lopane G, Mohamed S, Calandra-Buonaura G, Capellari S, De Massis P, Nassetti S, Perrone A, Riva R, Sambati L, Scaglione C, Cortelli P

doi: 10.1016/j.parkreldis.

Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation

Lancet Neurol.

Latourelle JC, Beste MT, Hadzi TC, Miller RE, Oppenheim JN, Valko MP, Wuest DM, Church BW, Khalil IG, Hayete B, Venuto CS

doi: 10.1016/

Aging and Cognitive Functions

Correlation of Visuospatial Ability and EEG Slowing in Patients with Parkinson's Disease

Parkinsons Dis.

Eichelberger D, Calabrese P, Meyer A, Chaturvedi M, Hatz F, Fuhr P, Gschwandtner U

doi: 10.1155/2017/3659784.

COMMENTED

Multiple Sclerosis

Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases

Read the related editorial recommended by Dr med. Andreas Hottinger: Parkinson Disease and Autoimmune Disorders-What Can We Learn From Genome-wide Pleiotropy?

doi: 10.1001/

Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease

NPJ Parkinsons Dis.

Odin P, Chaudhuri KR, Volkmann J, Antonini A, Storch A, Dietrichs E, Pirtošek Z, Henriksen T, Horne M, Devos D, Bergquist F

doi: 10.1038/s41531-018-0051-7.

Parkinson’s Disease

French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)

Parkinsonism Relat Disord.

Marques A, Vidal T, Pereira B, Benchetrit E, Socha J, Pineau F, Elbaz A, Artaud F, Mangone G, You H, Cormier F, Galitstky M, Pomies E, Rascol O, Derkinderen P, Weintraub D, Corvol JC, Durif F, DIGPD study group

doi: 10.1016/j.parkreldis.

Progression marker of Parkinson’s disease: a 4-year multi-site imaging study

Brain Neurology Journ.

Burciu RG, Ofori E, Archer DB, Wu SS, Pasternak O, McFarland NR, Okun MS, Vaillancourt DE

doi: 10.1093/brain/awx146.

Related content

Developing and validating Parkinson's disease subtypes and their motor and cognitive progression

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts

Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease

Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation

Correlation of Visuospatial Ability and EEG Slowing in Patients with Parkinson's Disease

Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases

Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease

French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)

Progression marker of Parkinson’s disease: a 4-year multi-site imaging study